Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study.

Helena Bleken ØstergaardValerie HumphreysEllen Margo HengeveldJulie Broe HonoréFrançois MachFrank L J Visseren Jan WesterinkGourav YadavLawrence A Leiternull null

Published in: Diabetes, obesity & metabolism (2022)

Life-years gained free of (recurrent) CVD by optimal CVRM and the addition of a GLP-1 RA or aSGLT-2i is dependent on baseline CVD status. These results aid individualizing prevention and promote shared decision-making in patients with T2D.

Keyphrases

type diabetes
cardiovascular disease
insulin resistance

disease activity
systemic lupus erythematosus

metabolic syndrome
interstitial lung disease

systemic sclerosis
skeletal muscle